| Literature DB >> 31726221 |
Rupak Shivakoti1, Jesmond Dalli2, Dileep Kadam3, Sanjay Gaikwad3, Madhusudan Barthwal4, Romain A Colas2, Francesca Mazzacuva2, Rahul Lokhande3, Sujata Dharmshale3, Renu Bharadwaj3, Anju Kagal3, Neeta Pradhan5, Sona Deshmukh5, Sachin Atre4, Tushar Sahasrabudhe4, Arjun Kakrani4, Vandana Kulkarni5, Swapnil Raskar5, Nishi Suryavanshi5, Sandy Chon6, Akshay Gupte6, Amita Gupta7, Nikhil Gupte7, María B Arriaga8, Kiyoshi F Fukutani9, Bruno B Andrade10, Jonathan E Golub11, Vidya Mave7.
Abstract
Individuals with concurrent tuberculosis (TB) and Type 2 diabetes (DM) have a higher risk of adverse outcomes. To better understand potential immunological differences, we utilized a comprehensive panel to characterize pro-inflammatory and pro-resolving (i.e., mediators involved in the resolution of inflammation) lipid mediators in individuals with TB and TB-DM. A nested cross-sectional study of 40 individuals (20 newly diagnosed DM and 20 without DM) was conducted within a cohort of individuals with active drug-susceptible treatment-naïve pulmonary TB. Lipid mediators were quantified in serum samples through lipid mediator profiling. We conducted correlation-based analysis of these mediators. Overall, the arachidonic acid-derived leukotriene and prostaglandin families were the most abundant pro-inflammatory lipid mediators, while lipoxins and maresins families were the most abundant pro-resolving lipid mediators in individuals with TB and TB-DM. Individuals with TB-DM had increased correlations and connectivity with both pro-inflammatory and pro-resolving lipid mediators compared to those with TB alone. We identified the most abundant lipid mediator metabolomes in circulation among individuals with TB and TB-DM; in addition, our data shows a substantial number of significant correlations between both pro-inflammatory and pro-resolving lipid mediators in individuals with TB-DM, delineating a molecular balance that potentially defines this comorbidity.Entities:
Keywords: Diabetes; Inflammation; Leukotrienes; Lipids; Lipoxins; Prostaglandins; Resolvins; Specialized pro-resolving mediators; Tuberculosis
Mesh:
Substances:
Year: 2019 PMID: 31726221 PMCID: PMC7067657 DOI: 10.1016/j.prostaglandins.2019.106398
Source DB: PubMed Journal: Prostaglandins Other Lipid Mediat ISSN: 1098-8823 Impact factor: 3.072